Company patents
University of Washington through its Center for Commercialization
University of Washington through its Center for Commercialization shows a surprising shift in its patent strategy, with a dominant focus on "Genetic & Microbiological Assays" (60.0% of its portfolio) despite a significant decline of -58.8% in 2025 and -42.9% so far in 2026. While "Pharmaceutical Preparations" and "Peptides & Proteins" saw rapid growth in 2024 (YoY +250.0% and +300.0% respectively), their patenting activity has sharply declined in 2025 and remained flat so far in 2026, indicating a potential re-evaluation of these emerging areas.
Patent Trend by Technology Area
Yearly patent publications since 2023
Product themes
Product-level themes inferred from filings since 2023, with category chips showing where each theme appears. Select a theme to filter the patents below.
70 US filings (since 2023) · 12 categories · 13 themes
Methods and reagents designed to improve the specificity, efficiency, or yield of nucleic acid capture, ligation, amplification, or library preparation steps, particularly for sequencing applications or quantitative analysis.
Methods and compositions for identifying, quantifying, or characterizing specific biological molecules (e.g., nucleic acids, proteins, metabolites, antibodies) or microbial species, often for diagnostic, prognostic, or quality control applications.
Self-contained or modular devices designed to automate and integrate multiple steps of molecular diagnostic assays, from sample preparation to result interpretation, often for point-of-care or high-throughput applications.
Development of therapeutic approaches involving the genetic modification of cells (e.g., T cells, stem cells, macrophages) or the use of viral/non-viral vectors to deliver genetic material for disease treatment.
Involves the design and synthesis of semiconductor or perovskite nanocrystals and other nanostructures with tailored optical and electronic properties for advanced applications in light-emitting devices, displays, or quantum technologies.
Design and synthesis of acyclic or carbocyclic organic compounds that selectively modulate specific biological targets or pathways for the treatment of diseases.
Assays leveraging CRISPR-Cas systems (e.g., Cas12, Cas13) for highly specific and sensitive detection of target nucleic acids, often involving collateral cleavage activity or reporter molecules.
Design and engineering of proteins or peptides to directly modulate immune responses, including enhancing antigen presentation, suppressing inflammation, or activating specific immune cell types.
Miniaturized devices that manipulate small volumes of fluids (nanoliters to picoliters) through microchannels to perform laboratory functions like mixing, separation, reaction, and detection on a single chip.
Identification and measurement of specific nucleic acid sequences (DNA, RNA), their expression levels, or epigenetic modifications (e.g., methylation) as indicators for disease presence, progression, risk, or treatment response.
Therapeutic strategies employing nucleic acids (DNA, RNA, oligonucleotides) to modulate gene expression, deliver genetic material, or interfere with disease-causing pathways. Includes gene therapy using viral vectors.
Techniques for precisely creating structures, patterns, or devices with feature sizes in the nanometer range, including various lithography methods, self-assembly, and controlled growth of nanowires or thin films.
Creation of membranes and surfaces with nanoscale features to control properties like porosity, hydrophobicity, or catalytic activity, particularly for applications in filtration, separation, and environmental remediation.
Patents
Showing 1-10 of 134